HUM Price Prediction Next Week
Technical Analysis: Based on recent price action, HUM has shown significant weakness, dropping to $255.91 on February 21, 2025, with a -5.67% decline in regular trading hours. The stock is currently trading well below its key moving averages, with SMA-200 at $312.84 and SMA-60 at $274.70, indicating a strong bearish trend.
RSI Analysis: The current RSI-14 reading of 39.44 suggests the stock is approaching oversold territory but hasn't reached extreme levels yet. The shorter-term RSI-6 at 36.17 shows increasing downside momentum.
Support/Resistance Levels:
- Key Fibonacci support levels:
- S1: $247.12
- S2: $237.96
- S3: $223.15
- Resistance levels:
- R1: $276.75
- R2: $285.91
- R3: $300.73
News Impact: Recent negative sentiment has been driven by:
- Justice Department's investigation into UnitedHealth Group affecting the entire healthcare sector
- Industry-wide challenges with rising medical costs
- Loss of approximately 30,000 D-SNP members due to redetermination
Price Prediction for Next Week (Feb 24-Mar 1, 2025): Given the technical indicators and negative news sentiment, HUM is likely to continue its downward trend. The stock is expected to test the first Fibonacci support level at $247.12.
Target price range:
- Bearish scenario (70% probability): $245-$250
- Base case (20% probability): $250-$255
- Bullish scenario (10% probability): $255-$260
Recommendation: SELL
- Current technical indicators and news sentiment suggest further downside
- Consider entering short positions with a stop loss at $262 (just above the 5-day SMA of $260.76)
- First target at $247.12, with potential to extend to $237.96 if market weakness persists
HUM Similar Chart Price Prediction
The price of HUM is predicted to go up 1.85%, based on the high correlation periods with PKX. The similarity of these two price pattern on the periods is 95.85%.
HUM
PKX
Up: 1.85%Similarity: 95.85%
HUM Revenue Forecast
HUM EPS Forecast
HUM FAQs
What is bull’s view on HUM?
What is bear's view on HUM?
What is HUM revenue forecast for next quarter？
What is HUM eps forecast for next quarter？
HUM VS S&P500
With its prowess in Medicare Advantage plans, Humana looks likely to benefit from strong demographic trends and increasing popularity of that program in the long run.
Humana enjoys industry-leading customer satisfaction metrics that positively influence its brand and reputation in the consumer-driven Medicare Advantage and Medicaid insurance sectors.
Humana's growth trajectory could rebound from current weakness, and we suspect the firm's 11%-15% annual EPS growth goal will remain possible in the long run.
HUM Analyst's Forecast
Andrew Mok
Barclays
Hold
2025-02-13
Price Target
$255 → $270
Upside
+6.37%
Barclays analyst Andrew Mok raised the firm's price target on Humana to $270 from $255 and keeps an Equal Weight rating on the shares. The firm maintains a cautious view on the upcoming Stars lawsuit decision, but acknowledges a more compelling risk/return profile for investors willing to absorb near-term volatility and look through to Humana's earnings growth in 2027 and beyond. Barclays assumes Humana can offset about 30% of the gross $3B stars headwind, which would result in a net $2B headwind worth about 210 basis points to Individual Medicare Advantage margin.
Erin Wright
Morgan Stanley
Hold
2025-02-12
Price Target
$301 → $285
Upside
+9.6%
Jessica Tassan
Piper Sandler
Hold
2025-01-15
Price Target
$270 → $288
Upside
+3.04%
